When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Leishmaniasis

  • Visão geral
  • Teoria
  • Diagnóstico
  • Tratamento
  • ACOMPANHAMENTO
  • Recursos
Última revisão: 12 Aug 2025
Última atualização: 12 Aug 2025

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • previous stay in endemic area
  • immunosuppression
  • prolonged fever
  • weight loss
  • ulcerative skin lesions
  • multiple nonulcerative skin nodules
  • destructive mucosal inflammation
  • splenomegaly
  • skin darkening
Detalhes completos

Outros fatores diagnósticos

  • fatigue
  • cough
  • headache
  • wasting
  • enlarged lymph nodes
  • hepatomegaly
  • previous antileishmanial treatment
  • epistaxis
  • abdominal pain
Detalhes completos

Fatores de risco

  • high exposure to sand fly bites
  • poverty
  • proximity to a patient with a history of infection
  • ownership of domestic animals
  • immunosuppression
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • CBC
  • liver function tests and BUN
  • serum human chorionic gonadotropin (hCG)
Detalhes completos

Investigações a serem consideradas

  • microscopic exam of relevant specimen
  • blood (buffy coat) or tissue culture
  • polymerase chain reaction (PCR)
  • serology
  • serum HIV testing
Detalhes completos

Algoritmo de tratamento

AGUDA

cutaneous leishmaniasis (CL)

mucosal leishmaniasis (ML)

visceral leishmaniasis (VL)

CONTÍNUA

post-kala-azar dermal leishmaniasis (PKDL)

relapse

Colaboradores

Autores

Naomi E. Aronson, MD

Professor of Medicine

Director, Infectious Diseases Division

Uniformed Services University of the Health Sciences

Bethesda

MD

Declarações

NEA receives federal grants to study leishmaniasis (received by NEA's institution USU), has given lectures on the topic of leishmaniasis at national and international meetings, and has a patent on biomarkers for leishmaniasis. NEA's institution USU has received royalties for her writing and editorial work for UpToDate. NEA is an unpaid member for the NIH/CDC/HIVMA guidelines group (the guideline is cited in this topic), and has chaired the IDSA/ASTMH guidelines (also cited in this topic). NEA is an author of a number of references cited in this topic. The views expressed in this topic are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, the Department of Defense, or the US Government.

Nathanial K. Copeland, MD, MTM&H

Assistant Professor of Medicine

Uniformed Services University of the Health Sciences

Bethesda

MD

Declarações

NKC is an author of a number of references cited in this topic. The views expressed in this topic are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, the Department of Defense, or the US Government.

Agradecimentos

Professor Naomi E. Aronson and Dr Nathanial K. Copeland would like to gratefully acknowledge Professor Richard Reithinger and Professor François Chappuis, previous contributors to this topic.

Declarações

RR and FC are authors of a number of references cited in this topic.

Revisores

Roberto Arenas, MD

Chief of the Mycology Section

Dr. Manuel Gea Gonzalez General Hospital

Mexico

Declarações

RA is the author of an article cited in this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Texto completo  Resumo

National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2024 [internet publication].Texto completo

Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Resumo

World Health Organization. Manual on case management and surveillance of the leishmaniases in the WHO European Region. July 2017 [internet publication].Texto completo

Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Resumo

Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Leishmaniasis images

  • Diagnósticos diferenciais

    • Hyperreactive malarial splenomegaly (HMS)
    • Malaria infection
    • Schistosomiasis
    Mais Diagnósticos diferenciais

  • Diretrizes

    • CDC Yellow Book: health information for international travel - leishmaniasis
    • CDC Yellow Book: health information for international travel - leishmaniasis
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal